DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > University Hospital > Articles in academic journal >

The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer

File Description SizeFormat
CCO9_29.pdf206.74 kBAdobe PDFView/Open

Title: The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer
Authors: Oikawa, Masahiro
Issue Date: Jun-2020
Publisher: AME Publishing Company
Citation: Chinese clinical oncology, 9(3), art.no.29; 2020
Abstract: Chemotherapy has played a significant role in breast cancer therapy and dramatically improved the outcome of breast cancer patients. Neoadjuvant chemotherapy (NAC) is defined as chemotherapy conducted before surgery. The rationale for NAC in operable breast cancer is that the benefit of systemic chemotherapy on the long-term prognosis does not change, regardless of whether chemotherapy is conducted before or after surgery. NAC is now widely used for early and advanced breast cancer patients since it has two significant advantages over conventional adjuvant chemotherapy after surgery. One is that the rate of the breast-conserving surgery increase resulted from tumor shrinkage during NAC, which can contribute to a minimal invasion from surgical therapy and good quality of life following therapy. Another is that a response to chemotherapy can be observed in in-vivo setting. Patients who achieve the pathological complete response (pCR) show a favorable prognosis. Thus, the response to NAC can be used as an indicator for personalized medicine. To date, novel agents for NAC have been explored in randomized trials, setting the pCR rate as an endpoint. Also, response- and residual disease-guided therapy have been ready for prime time in daily practice. The author describes the history, current situation, and future direction of NAC for HER2-negative breast cancer in the review article.
Keywords: Breast cancer / neoadjuvant chemotherapy (NAC) / pathological complete response (pCR) / response- and residual disease-guided therapy
URI: http://hdl.handle.net/10069/40141
ISSN: 23043865
DOI: 10.21037/cco-20-12
Rights: © Chinese Clinical Oncology. This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:https://creativecommons.org/licenses/by-nc-nd/4.0/.
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/40141

All items in NAOSITE are protected by copyright, with all rights reserved.


Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace